Research Monitoring
What changed
in the evidence.
Evidence is not static, and neither are our grades. This is the public log of what moved — new trials, regulatory actions, and every time we changed a compound's grade, with the source that prompted it.
Recent trial activity
Auto-updated from ClinicalTrials.gov · synced 2026-07-12Not yet recruiting
Imaging in Semaglutide Study
Recruiting
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Recruiting
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.
Completed
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
Recruiting
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
Recruiting
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Completed
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
Recruiting
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Completed
A Study of LY3502970 in Healthy Participants
Withdrawn
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
Evidence-grade change log
July 2026
Editorial
Synptide launches the compound directory and evidence-grading system
We published canonical, outcome-graded profiles for the first 25 compounds, plus a public A–U evidence framework and this change log.
Evidence-grade change
Semaglutide graded A for cardiovascular risk reduction on SELECT evidence
We set semaglutide's cardiovascular-outcome grade to A after the SELECT trial's 20% reduction in major cardiovascular events in people with obesity but without diabetes.